Due to its known human teratogenicity, even following a single dose, THALOMID® (thalidomide) is contraindicated in females who are pregnant and females at risk of becoming pregnant. REVLIMID® (lenalidomide) and POMALYST® (pomalidomide) are contraindicated in pregnant women and women at risk of becoming pregnant. To avoid embryo-fetal exposure, REVLIMID®, POMALYST® and THALOMID® are only available through a controlled distribution program called RevAid®. RevAid® monitors critical activities and ensures all program requirements are met before the drug is released to a patient.- • Only prescribers who are registered and agree to meet all the conditions of the RevAid® program will have access to REVLIMID®, POMALYST® and THALOMID®.
- • Only patients who are enrolled in RevAid® by their registered physician, and agree to comply with the requirements of the RevAid® program will receive REVLIMID®, POMALYST® or THALOMID®.
- • Only pharmacists registered with the RevAid® can dispense REVLIMID®, POMALYST® or THALOMID®.
|
|
For more information, please call
1-888-RevAid1 (1-888-738-2431) or contact your Celgene Representative.
|
|
To become a registered prescriber within the RevAid®
program please print, fill out and fax the registration form
to 1-877-585-2382.
Prescriber Registration Form
|
|
You must be enrolled in the RevAid® program to receive REVLIMID®, POMALYST® or THALOMID® OR to further access information on this website. Please contact your healthcare professional for additional information.
If your doctor has prescribed REVLIMID®, POMALYST® or THALOMID® as part of your treatment regimen, you can login to the RevAid® program with the unique ID and passcode provided by your RevAid® representative.
|
|
Pharmacies must be enrolled in the RevAid® program and continue to meet RevAid® certification requirements on an ongoing basis in order to dispense REVLIMID®, POMALYST® or THALOMID® in Canada.
Pharmacy Information
|